banner
N-Acetylgalactosaminyltransferase Engineering Service

N-Acetylgalactosaminyltransferase Engineering Service

Functions of Polypeptide N-acetylgalactosaminyltransferase (GALNT)

Glycosylation modification is an important post-translational modification of proteins. According to the different ways of linking the sugar chain and protein, glycosylation modification is mainly divided into two types: N-glycosylation and O-glycosylation. One of the most common O-glycosylation modifications is mucin-type O-glycosylation. With continuous research, more and more tumor markers are being discovered. These include several members of the GALNT family, which is the initiating enzyme that catalyzes mucin-type O-glycosylation. It affects the O-glycosylation of mucins, thereby influencing tumor cell genesis, prognosis, proliferation, and migration. To date, 20 isoforms of GALNT have been identified in humans. There are lots of research reports on GALNT related to cancer and other diseases.

The ability to precisely engineer GALNT to control glycosylation patterns is a major frontier in biotechnology, offering unprecedented opportunities to optimize therapeutic proteins and unlock new biological insights. At CD BioGlyco, our specialized GALNT engineering service is designed to harness this potential, providing a sophisticated platform for modifying proteins with high precision and efficacy.

Key Technologies

To overcome the inherent challenges of engineering glycosyltransferases, we employ precise gene editing technologies to design biological solutions with uniquely optimized properties tailored to your specific application. Our services range from improving enzyme kinetics to increase productivity to altering substrate specificity to develop unnatural glycans.

Driving Innovation Through Precision Glycoengineering with GALNT

CD BioGlyco is committed to being a reliable GALNT gene modification service partner. We have rich experience in cell lines and animal model construction.

One-stop GALNT gene modification process.Fig.1 One-stop GALNT gene modification process. (CD BioGlyco)

  • Various GALNT gene modification service
    Animal and cell line models are powerful tools for biomedical research. We have various types of mice and cell line models such as cancer cells, bone cells, etc. According to customers' needs, we develop Gene Editing Programs and construct gene modification models. Through overexpression, knockout, knockdown, and other different gene modification methods, we study the specific substrate of GALNT, its physiological function, and its application in the treatment of diseases.

GALNT2

GALNT2 modifies the O-glycosylation of ITGA5. It affects the activation of PI3K/Akt and MAPK/ERK pathways. Studies have shown that the knockdown of GALNT2 inhibits cell proliferation, migration, and invasion of non-small cell lung carcinoma cells. While the overexpression of GALNT2 resulted in the opposite.

GALNT3

GALNT3 affects the differentiation and prognosis of colon cancer cells. It may be a reliable diagnostic indicator for colon cancer. GALNT3 also affects the LDN-glycosylation of sclerostin, which may open up a new tool for the treatment of bone-specific osteoporosis.

GALNT6

GALNT6 is used as a molecular diagnostic marker for mammary carcinoma cell proliferation. Knockdown of GALNT6 inhibits cell migration and invasion of hepatocellular carcinoma (HCC) cells.

GALNT13

GALNT13 is highly correlated with the development and prognosis of myeloid neuroblastoma. It is used as a molecular marker for the diagnosis of myeloid neuroblastoma.

GALNT14

Mucin-type O-glycosylation in cancer varies in structure and amount, culminating in a unique glycan structure. GALNT14 plays an important role in a wide range of biological activities, including tumorigenesis, progression, invasion, migration, and apoptosis.

Workflow

GalNAc-T engineering service. (CD BioGlyco)

Published Data

Paper Title: B4GALNT3 regulates glycosylation of sclerostin and bone mass

Technology: Gene Knockout, Gene Overexpression, Gene Silencing

Journal: EBioMedicine

IF: 11.1

Published: 2023

Results: B4GALNT3 expresses β-1,4-N-acetylgalactosaminyltransferase 3. Serum total sclerostin levels were elevated but serum LDN-glycosylated sclerostin levels were decreased in B4GALNT3 knockout mice compared to controls. The silencing of B4GALNT3 decreased the levels of LDN-glycosylated sclerostin, whereas overexpression of B4GALNT3 decreased the levels. B4GALNT3-mediated LDN-glycosylation of sclerostin may be a target for bone-specific osteoporosis.

Changes in sclerostin levels in B4galnt3 knockout mice.Fig. 2 Changes in sclerostin levels in B4galnt3 knockout mice. (Movérare-Skrtic, et al., 2023)

Applications

  • GALNT has diverse functions in different biological behaviors of tumor cells. Technologies for GALNT gene editing are used to develop new means of suppressing cancer cells.
  • Technologies for GALNT gene editing are important for the study of the regulatory mechanisms of glycosylation and the functional roles of glycoproteins in life activities.
  • Technologies for GALNT gene editing are used for the role of GALNT in inflammation and other diseases, which is expected to provide possible ideas for the search for novel markers and drug targets.

Advantages

  • We optimize the experimental conditions. We improve the positive rate while reducing cytotoxicity, and have high editing efficiency and low off-target rate.
  • We have a professional gene editing team to provide clients with experimental design, troubleshooting, data analysis, and other services.
  • We provide a one-stop service for GALNT gene editing. Sequence design, vector construction, mutant construction, and other experiments can be completed.

Frequently Asked Questions

CD BioGlyco has undergone continuous research to minimize the time required to prepare gene-edited cells and animal models. We use optimized technologies for gene editing to precisely modify genes. If you are interested in our GALNT gene modification service, please feel free to contact us.

Associated Services

To further bolster your research and development endeavors, CD BioGlyco provides a suite of supplementary services that integrate seamlessly with your GALNT engineering project. Our objective is to deliver a holistic, start-to-finish solution addressing all your glycobiology requirements.

(AI-CD BioGlyco)

Glycosylation Analysis: We deliver extensive services for in-depth examination of glycan structures. This encompasses determining the exact sequence of monosaccharides within your glycan chain, identifying the specific glycosidic bond types linking sugar units, and employing high-resolution mass spectrometry (MS) to detect and quantify glycan structures.

(CD BioGlyco)

Glyco-engineered Expression: Our cutting-edge facilities offer tailored protein expression services for producing your target protein. We provide multiple expression systems, such as mammalian cell expression, Pichia pastoris expression, and plant-based expression systems.

Reference

  1. Movérare-Skrtic, S.; et al. B4GALNT3 regulates glycosylation of sclerostin and bone mass. EBioMedicine. 2023, 91: 104546. (Open Access)
This service is for Research Use Only, not intended for any clinical use.
Quick Links
Resources

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0